newsfilter
← Latest News
GlobeNewswire·

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong Balance Sheet with